Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenetic Biosciences (XEN)

  Print      Mail a friend

Monday 23 January, 2012

Xenetic Biosciences

Statement re. Press Comment

RNS Number : 9673V
Xenetic Biosciences PLC
23 January 2012

Xenetic Biosciences plc

('Xenetic' or 'the Company')


Serum Institute of India ('Serum'/'SIIL') remains committed shareholder to Xenetic for the Long Term


Xenetic Biosciences plc (LSE: XEN.L), is a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs. Its collaboration with the Serum Institute of India (its second largest shareholder holding a circa 12% equity interest in the Company) has thrived for many years and lies at the heart of a number of Xenetic's key development programmes.


Following a report published on Friday 20th January 2012 in The Economic Times (India), the boards of both Serum and Xenetic wish to clarify that there is absolutely no truth in the statements made in the article as they pertain to Xenetic Biosciences.


Adar Poonawalla, Executive Director of Serum (and son of the Founder, Dr Cyrus Poonawalla) commenting on the report said: 


"The commitment to Xenetic will continue on a long-term basis, as Serum has already spent millions buying shares in Xenetic, set up specific facilities for manufacture of Polysialyic acid (PSA) and expended US$3.5 million on the clinical trials for PSA EPO.  Recently, Serum has subscribed to shares at 11p to reinforce its long term commitment to Xenetic.  We are also partnered with Xenetic on supplying PSA to Baxter for Factor VIII.  At no time since 2007 has Serum Institute of India contemplated selling its interest in Xenetic Biosciences and this steadfastly remains the case."


Commenting alongside Adar Poonawalla, M. Scott Maguire, CEO of Xenetic, said: "The commitment from Serum on these important programs was never in doubt in my mind as I have the highest regard and respect for the level of scientific and clinical development effort that Serum has made over the years and will continue to do so.  It is, of course, distressing when the press gets it so badly wrong, and I am therefore delighted that Adar Poonawalla has been both quick and forceful in making this fulsome statement of support for Xenetic.


ErepoXen™, our jointly owned PSA-EPO candidate, has already delivered excellent results in its recently completed Phase IIa clinical trials and will soon move into Phase IIb. This is a product which will address a $9B global market and both Serum and Xenetic have high expectations of its potential long-term commercial success. Serum is our sole current supplier of PSA, the naturally -occurring  polymer at the core of our increasingly successful PolyXen™ platform technology that is being applied to such excellent clinical development effect in both the ErepoXen and Baxter programmes, along with a number of other promising  PolyXen™ initiatives currently in pre-clinical development.


The relationship between the two companies has been, and will remain strong, bolstered by the extensive joint programs that are progressing towards commercial success."


- Ends -



Xenetic Biosciences plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (NOMAD & Broker)

+44 (0)20 3205 7500

Claes Spång

Walbrook PR

+44 (0)20 7933 8780

Paul McManus

[email protected]

Paul Cornelius

[email protected]


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t